MedTrace Logo

Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

NCT03562897 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-07-06

No results posted yet for this study

Summary

Our hypothesis is: the nutritional supplement Ocoxin-viusid improves the quality of life of patients, including a better tolerance to neoadjuvant chemotherapy.

Conditions

  • Carcinoma
  • Ovarian Neoplasm
  • Endocrine Gland Neoplasm
  • Urogenital Neoplasms
  • Ovarian Diseases
  • Adnexal Diseases
  • Genital Diseases, Female
  • Female Urogenital Diseases
  • Female Urogenital Diseases and Pregnancy Complications
  • Endocrine System Diseases
  • Gonadal Disorders
  • Genital Neoplasm, Female
  • Neoplasms, Glandular and Epithelial

Interventions

DIETARY_SUPPLEMENT

Ocoxin-Viusid

Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).

Sponsors & Collaborators

  • Catalysis SL

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-25
Primary Completion
2022-02-15
Completion
2022-06-15

Countries

  • Cuba

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03562897 on ClinicalTrials.gov